Browse by author
Lookup NU author(s): Dr Aaron Liew
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Cell therapy has enormous potential for the treatment of conditions of unmet medical need. Cell therapy may be applied to diabetes mellitus in the context of beta cell replacement or for the treatment of diabetic complications. A large number of cell types including hematopoietic stem cells, mesenchymal stem cells, umbilical cord blood, conditioned lymphocytes, mononuclear cells, or a combination of these cells have been shown to be safe and feasible for the treatment of patients with diabetes mellitus. The first part of this review article will focus on the current perspective of the role of embryonic stem cells and inducible pluripotent stem cells for beta cell replacement and the current clinical data on cell-based therapy for the restoration of normoglycemia. The second part of this review will highlight the therapeutic role of MSCs in islet cells cotransplantation and the management of diabetes related vascular complications.
Author(s): Liew A, O'Brien T
Publication type: Review
Publication status: Published
Journal: Current Diabetes Reports
Year: 2014
Volume: 14
Issue: 3
Pages: 1-11
Print publication date: 28/01/2014
ISSN (print): 1534-4827
ISSN (electronic): 1539-0829
URL: http://dx.doi.org/10.1007/s11892-013-0469-6
DOI: 10.1007/s11892-013-0469-6
PubMed id: 24464340
